Relmada Therapeutics, Inc. (RLMD) — Financial statements
Income statement, balance sheet, and cash flow for Relmada Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.74↓98.4% | 46↓15.7% | 55↓51.6% | 113↑25.0% | 91 | |
| General & Administrative Expenses | 0.31↓99.2% | 38↓22.9% | 49↑2.0% | 48↑36.6% | 35 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 0.31↓99.2% | 38↓22.9% | 49↑2.0% | 48↑36.6% | 35 | |
| Other Expenses | 58 | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | |
| Operating Expenses | 59↓29.6% | 84↓19.1% | 104↓35.7% | 161↑28.3% | 126 | |
| Total Costs & Expenses | 59↓29.6% | 84↓19.1% | 104↓35.7% | 161↑28.3% | 126 | |
| Operating Results | ||||||
| Operating Income | -59↑29.6% | -84↑19.1% | -104↑35.7% | -161↓28.3% | -126 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 104↑5185000.0% | 0.00↑59.0% | 0.00 | |
| EBITDA | -59↑29.6% | -84↓1808.6% | 5↑103.0% | -161↓28.3% | -126 | |
| EBIT | -59↑29.6% | -84↑15.1% | -99↑38.7% | -161↓28.3% | -126 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↓60.5% | 4↓31.5% | 5↑93.7% | 3↑121.8% | 1 | |
| Interest Income | 1↓60.5% | 4↓31.5% | 5↑93.7% | 3↑121.8% | 1 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -5 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↓56.2% | 4↓20.3% | 5↑16.7% | 4↑8805.0% | -0.05 | |
| Income Before Tax | -57↑28.3% | -80↑19.0% | -99↑37.1% | -157↓24.9% | -126 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -57↑28.3% | -80↑19.0% | -99↑37.1% | -157↓24.9% | -126 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -57↑28.3% | -80↑19.0% | -99↑37.1% | -157↓24.9% | -126 | |
| Bottom-Line Net Income | -57↑28.3% | -80↑19.0% | -99↑37.1% | -157↓24.9% | -126 | |
| EPS (Basic) | -1.45↑45.3% | -2.65↑19.2% | -3.28↑38.1% | -5.30↑26.0% | -7.16 | |
| EPS (Diluted) | -1.45↑45.3% | -2.65↑19.2% | -3.28↑38.1% | -5.30↑26.0% | -7.16 | |
| Weighted Average Shares | 39↑30.9% | 30↑0.2% | 30↑1.6% | 30↑68.8% | 18 | |
| Weighted Average Diluted Shares | 39↑30.9% | 30↑0.2% | 30↑1.6% | 30↑68.8% | 18 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.